pCR of 37 Percent for Topical Imiquimod in Lentigo Maligna

Share this content:
pCR of 37 Percent for Topical Imiquimod in Lentigo Maligna
pCR of 37 Percent for Topical Imiquimod in Lentigo Maligna

FRIDAY, Oct. 21, 2016 (HealthDay News) -- For patients with lentigo maligna (LM) in-situ melanoma, topical imiquimod has a pathological complete regression (pCR) rate of 37 percent, according to a study published online Oct. 6 in the British Journal of Dermatology.

Jeremy R. Marsden, M.D., from the University Hospital Birmingham NHS Foundation Trust in the United Kingdom, and colleagues estimated pCR for LM following imiquimod in a single-arm phase II trial. Data were included for 60 imiquimod applications over 12 weeks for LM, then radical resection.

The researchers found that the pCR rate was 37 percent (10/27). Twelve of 28 patients had clinical complete remission plus negative biopsies, of whom seven out of 11 had pCR on subsequent surgery. The median dose intensity was 86.7 percent. If the cure rate for imiquimod was 80 percent, eight of 16 surveyed patients preferred primary imiquimod over surgery compared with four of 16 patients if the cure rate was ≤50 percent.

"The pCR rate was insufficient to justify phase III investigation of imiquimod versus surgery. Clinical complete response and negative targeted biopsies left uncertainty regarding pathological clearance," the authors write. "Some patients would trade less aggressive treatment of LM against efficacy."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical Trial

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical ...

Clovers trial seeks to determine which IV fluids, vasopressors combo works best to curb sepsis

Education Can Up Emotional Intelligence in Residents

Education Can Up Emotional Intelligence in Residents

Increase in total EI median scores, stress management composite score after intervention

Cancer-Related Gene Variations Frequently Reclassified

Cancer-Related Gene Variations Frequently Reclassified

24.9 percent of variants of uncertain significance were reclassified at a single commercial laboratory

is free, fast, and customized just for you!




Already a member?

Sign In Now »